Ligand Pharmaceuticals/$LGND
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
- Ticker
- $LGND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 47
- Headquarters
- Jupiter, United States
- Website
- www.ligand.com
LGND Metrics
BasicAdvanced
$6B
124.91
$2.39
1.01
-
Price and volume
Market cap
$6B
Beta
1.01
52-week high
$326.63
52-week low
$175.89
Average daily volume
225K
Financial strength
Current ratio
13.345
Quick ratio
13.345
Long term debt to equity
0.729
Total debt to equity
1.173
Interest coverage (TTM)
4.46%
Profitability
EBITDA (TTM)
117.036
Gross margin (TTM)
86.12%
Net profit margin (TTM)
16.77%
Operating margin (TTM)
33.16%
Effective tax rate (TTM)
2.41%
Revenue per employee (TTM)
$5,400,000
Management effectiveness
Return on assets (TTM)
2.83%
Return on equity (TTM)
5.38%
Valuation
Price to earnings (TTM)
124.906
Price to revenue (TTM)
23.29
Price to book
6.21
Price to tangible book (TTM)
13.22
Price to free cash flow (TTM)
65.229
Free cash flow yield (TTM)
1.53%
Free cash flow per share (TTM)
4.579
Growth
Revenue change (TTM)
1.03%
Earnings per share change (TTM)
-3.97%
3-year revenue growth (CAGR)
18.23%
10-year revenue growth (CAGR)
12.81%
3-year earnings per share growth (CAGR)
36.08%
10-year earnings per share growth (CAGR)
21.21%
What the Analysts think about LGND
Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.
Analyst projections of the future price of Ligand Pharmaceuticals stock.
Bulls say / Bears say
Royalty revenue rose 51% year on year to $70.3 million in the third quarter, and Ligand raised its full-year adjusted EPS outlook to $9.50–$9.75. That points to strong growth in its core royalty business. (Ligand Pharmaceuticals)
The XOMA acquisition added seven marketed products and 14 late-stage programmes, more than doubling Ligand’s portfolio to over 200 royalty assets. This broadens its sources of potential royalty income beyond its existing products. (Ligand Pharmaceuticals)
Palvella’s QTORIN rapamycin has received FDA priority review, with a decision due by 28 February 2027. If approved, Ligand is entitled to royalties of 8%–9.8%, offering a potential new source of growth. (The Motley Fool)
Ligand reported a $28.5 million net loss in the third quarter despite higher royalties, including a $35.7 million loss from changes in the fair value of investments. This shows reported earnings can be volatile even when operating royalties grow. (SEC)
Captisol sales fell to $7.9 million from $10.7 million in the third quarter, and were down year on year over the first nine months as well. Ligand says order timing affects these sales, making this revenue stream less predictable. (Ligand Pharmaceuticals)
Ligand’s partner Ovid said soticlestat narrowly missed the primary endpoint in a Phase 3 Dravet syndrome trial. The setback highlights that some pipeline assets may fail to deliver expected future milestones or royalties. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
LGND Financial Performance
Revenues and expenses
LGND Earnings Performance
Company profitability
Upcoming events
No upcoming events
LGND News
AllArticlesVideos
Funds containing LGND
Fund name | Fund size | $LGND weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.6B | 0.59% |
iShares Healthcare Innovation£DRDR | $1.6B | 0.59% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.59% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.39% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.39% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

